Lumina Bio — 100% in-silico drug discovery for hard targets

Why we exist

When a target fights back, we re-route.

Drug discovery is slow and expensive, and it stalls most often on the targets that matter most — the hard ones, the ones called undruggable. Many teams have a good target but no clear path to a molecule.

We route around that bottleneck with computational design and multi-layer validation. When one approach is blocked, we find another path — inhibition gives way to degradation, one chemistry to another — where conventional discovery stops.

We do not screen millions by brute force. We aim, carefully, at a small number of well-understood candidates. Precision is the strategy.

The platform

One pipeline, from a target to a validated candidate.

Our proprietary platform runs a single, sequential pipeline: generate novel molecules, filter them through independent computational gates, and accumulate what we learn. Each stage is built to remove the false positives the previous stage could not see.

01 — Generate

Create

Novel molecules designed directly in the target's binding site — not screened from known libraries.

02 — Cross-validate

Confirm

Independent, orthogonal methods at every stage, so one signal never decides.

03 — Accumulate

Compound

Every result — including negative ones — feeds the platform and sharpens the next design.

01Generative design Create novel candidate molecules for the target.

02AI binding prediction Rapidly triage promising binders from the rest.

03Structure-based docking Predict how a molecule sits in the binding site.

04Molecular dynamics Test whether the binding holds over time.

05Free-energy methods Quantify binding strength on a physical basis.

06ADMET & drug-likeness Evaluate absorption, metabolism, safety, and more.

07Synthesizability Confirm a real, viable route to make it.

08Novelty screening Check it is distinct enough to protect.

→ Validated candidate A molecule that has passed every independent gate.

Validation discipline

We trust no single signal.

A good docking score is not binding. Binding is not potency. Each layer must be independently confirmed — and this discipline is what separates a real candidate from a computational artifact.

Principle 01

Distrust single metrics

No one score decides. Binding prediction, dynamic stability, and free energy each say something different — and any of them can reverse the verdict.

Principle 02

Independent cross-validation

We confirm with methods built on different principles. Synthesizability is checked several ways; free energy is computed by two mathematical routes at once.

Principle 03

Prediction meets measurement

We compare predictions against real measurements and correct the next prediction with the gap. The platform grows more accurate the more it is used.

The real asset is not any single molecule. A candidate list ages; the ability to design better molecules — and the discipline to validate them — does not. Every project deepens the platform.

Targeted protein degradation

Small-molecule degraders, designed computationally.

Targeted protein degradation goes beyond blocking a protein's activity — it harnesses the cell's own machinery to remove the target entirely, offering a route past resistance and toward targets long considered undruggable.

Lumina Bio focuses on the computational design of small-molecule degraders. A core strength is predicting the ternary complex — target, degrader, and the cell's degradation machinery — and assessing its stability through long-timescale dynamics. We design bifunctional (PROTAC) candidates today, on a foundation built to extend across small-molecule degradation strategies.

PROTAC — current focus Molecular glue — extension Antibody-based — out of scope

An honest boundary

Computational prediction of ternary-complex formation is evidence of degradation potential — not proof of degradation. What computation can answer, and what must be confirmed in the lab, we keep clearly separate.

Services

Where our partners come in.

We develop our own pipeline — and we put the platform to work for other teams. Partners enter at different points; we meet them there.

Entry 01

Strong chemistry, no in-silico

You have an excellent medicinal chemistry team but no computational design capability. We design candidates for your target; you synthesize.

Entry 02

Capability, no compute

You have molecules but not the infrastructure to run large-scale simulation and precise calculation. We validate them on our own GPU pipeline.

Entry 03

Biology, meet computation

We connect target biology and molecular simulation in one integrated pipeline.

In-silico DesignNovel candidates designed for your target.

Multi-stage ValidationYour molecules, put through the full gauntlet.

Synthesis CoordinationSynthetic routes and external CRO synthesis, coordinated.

Hard-Target StrategyWorkaround design for targets that resist.

Milestone PartnershipMilestone-based, with joint-IP options.

Advisory RetainerOngoing in-silico support, month to month.

Your data

On-premise, private

We run our own on-premise GPU infrastructure — so your project is never bottlenecked by rented compute, and your data never sits on someone else's cloud.

Your IP

Your target, your terms

We work under NDA, share results — not our engine — and never repurpose your target for anyone else.

No risk to start

Start with a free pilot.

New to us? We take your target and deliver an initial in-silico design pass at no cost. If you like it, we scope a paid engagement. Your structures stay yours — always under NDA.

Request a pilot

Pipeline

What the platform has produced.

These are in-silico validated assets — evidence that the platform carries a candidate all the way through. They are not clinical-stage programs; wet-lab validation lies ahead.

Program	Target	Modality	Stage	Status
Neurodegeneration / Alzheimer's	Tau-related kinase	Small molecule	In-silico validated (through free-energy)	Binding-assay ready
Neurodegeneration / Alzheimer's	Multi-kinase (triple)	Small molecule	In-silico screening	Ongoing
Oncology	Oncogenic driver (hard target)	Targeted degrader	In-silico champion	IP-clean
Oncology	Oncogenic driver (CNS context)	Small molecule	Exploration	Early

Stages: Design → Multi-stage validation → Free-energy → Synthesis → Binding assay → in-vivo PoC → Partnering

Shown as evidence of capability, not as approved or clinical-stage medicines. Specific structures and figures are withheld pending IP protection.

Company

Built from the ground up, for precision.

We believe the next generation of medicines can be designed — computationally, rigorously, and for the targets the world has given up on. We build that capability, and prove it one validated molecule at a time.

Lumina Bio was founded by Jae Yong Choi, who built the platform and its on-premise infrastructure from the ground up — teaching himself molecular biology, pharmacology, and computational chemistry along the way.

CompanyLumina Bio Co., Ltd.

CEOChoi, Jae Yong

LocationNaju, Jeollanam-do, Republic of Korea

FocusIn-silico small-molecule drug discovery

Contact

Have a hard target? Let's take a first pass.

For partnership, licensing, and scientific collaboration. Detailed compound data is exchanged only under NDA, and we reply within business days.

Prefer email? Reach us directly:

Inquiries inquiry@luminabio.net

Administration main.admin@luminabio.net

We design drug candidates for the targets others can't.

Designed by computation

Multi-layer discipline

A way around the wall